Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2010-03-26

Last Posted Date: 2018-03-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT01094184

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2

Completed

Conditions: Ovarian Carcinoma
Breast Carcinoma
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Alisertib
Drug: Paclitaxel

First Posted Date: 2010-03-24

Last Posted Date: 2018-06-04

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 191

Registration Number: NCT01091428

Evaluate Safety, Efficacy and Pharmacokinetics

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: CT-P6
Drug: Herceptin
Drug: Paclitaxel

First Posted Date: 2010-03-11

Last Posted Date: 2024-08-06

Lead Sponsor: Celltrion

Target Recruit Count: 174

Registration Number: NCT01084863

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: CT-P6
Drug: Herceptin
Drug: Paclitaxel

First Posted Date: 2010-03-11

Last Posted Date: 2024-08-30

Lead Sponsor: Celltrion

Target Recruit Count: 475

Registration Number: NCT01084876

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Phase 2

Completed

Conditions: Precancerous Condition
Head and Neck Cancer

Interventions: Biological: cetuximab
Radiation: intensity-modulated radiation therapy (IMRT)
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2010-03-10

Last Posted Date: 2023-06-28

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 90

Registration Number: NCT01084083

Locations: 🇺🇸
Northwest Ohio Oncology Center, Maumee, Ohio, United States
🇺🇸
McKee Medical Center, Loveland, Colorado, United States
🇺🇸
Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States

and more 118 locations

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer
Bowel Obstruction

Interventions: Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2010-03-09

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT01083537

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: paclitaxel
Drug: olaparib
Drug: carboplatin

First Posted Date: 2010-03-05

Last Posted Date: 2024-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 162

Registration Number: NCT01081951

Locations: 🇬🇧
Research Site, Edinburgh, United Kingdom

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3

Active, not recruiting

Conditions: Borderline Ovarian Mucinous Tumor
Stage IA Ovarian Cancer AJCC v6 and v7
Recurrent Fallopian Tube Carcinoma
Stage IIA Fallopian Tube Cancer AJCC v6 and v7
Stage IIB Ovarian Cancer AJCC v6 and v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Stage IIIC Ovarian Cancer AJCC v6 and v7
Ovarian Mucinous Cystadenocarcinoma
Recurrent Ovarian Carcinoma
Stage IC Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Capecitabine
Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2010-03-05

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT01081262

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

and more 245 locations